185 related articles for article (PubMed ID: 28609585)
1. Immunoexpression of p16 in uterine leiomyomas with infarct-type necrosis: an analysis of 35 cases.
Ip PP; Lim D; Cheung ANY; Oliva E
Histopathology; 2017 Nov; 71(5):743-750. PubMed ID: 28609585
[TBL] [Abstract][Full Text] [Related]
2. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
[TBL] [Abstract][Full Text] [Related]
4. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.
Ip PP; Cheung AN; Clement PB
Am J Surg Pathol; 2009 Jul; 33(7):992-1005. PubMed ID: 19417585
[TBL] [Abstract][Full Text] [Related]
5. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
Chen L; Yang B
Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
[TBL] [Abstract][Full Text] [Related]
7. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors.
Lee CH; Turbin DA; Sung YC; Espinosa I; Montgomery K; van de Rijn M; Gilks CB
Mod Pathol; 2009 Dec; 22(12):1519-31. PubMed ID: 19734847
[TBL] [Abstract][Full Text] [Related]
8. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of progesterone receptor, p16, p53 and pHH3 expression in uterine atypical leiomyoma.
Liang Y; Zhang X; Chen X; Lü W
Int J Clin Exp Pathol; 2015; 8(6):7196-202. PubMed ID: 26261614
[TBL] [Abstract][Full Text] [Related]
10. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
Shanes ED; Friedman LA; Mills AM
Am J Surg Pathol; 2019 Jun; 43(6):792-801. PubMed ID: 31009388
[TBL] [Abstract][Full Text] [Related]
12. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
[TBL] [Abstract][Full Text] [Related]
13. Unusual morphological features of uterine leiomyomas treated with progestogens.
Boyd C; McCluggage WG
J Clin Pathol; 2011 Jun; 64(6):485-9. PubMed ID: 21398323
[TBL] [Abstract][Full Text] [Related]
14. Biomarker resolution of uterine smooth muscle tumor necrosis as benign vs malignant.
Yang EJ; Mutter GL
Mod Pathol; 2015 Jun; 28(6):830-5. PubMed ID: 25698060
[TBL] [Abstract][Full Text] [Related]
15. Atypical uterine leiomyoma: a case report and review of the literature.
Manxhuka-Kerliu S; Kerliu-Saliu I; Sahatciu-Meka V; Kerliu L; Shahini L
J Med Case Rep; 2016 Jan; 10():22. PubMed ID: 26801982
[TBL] [Abstract][Full Text] [Related]
16. Differential Immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants.
Gannon BR; Manduch M; Childs TJ
Int J Gynecol Pathol; 2008 Jan; 27(1):68-73. PubMed ID: 18156978
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle regulatory markers in uterine atypical leiomyoma and leiomyosarcoma: immunohistochemical study of 68 cases with clinical follow-up.
Mills AM; Ly A; Balzer BL; Hendrickson MR; Kempson RL; McKenney JK; Longacre TA
Am J Surg Pathol; 2013 May; 37(5):634-42. PubMed ID: 23552380
[TBL] [Abstract][Full Text] [Related]
18. Smooth muscle neoplasms of the urinary bladder: a clinicopathologic study of 51 cases.
Lee TK; Miyamoto H; Osunkoya AO; Guo CC; Weiss SW; Epstein JI
Am J Surg Pathol; 2010 Apr; 34(4):502-9. PubMed ID: 20154594
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
20. Pathological characteristics and clinical outcome of uterine leiomyomas associated with pregnancy.
Muezzinoglu B; Corakci A
Pathol Res Pract; 2011 Nov; 207(11):691-4. PubMed ID: 21993296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]